Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
AMD Therapeutics LLC is managing 2 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are distributed across 2 distinct examiners, indicating that the company is dealing with multiple reviewers. The prosecution is also spread across 2 distinct art units, suggesting a diverse set of technological inquiries within the sector. This distribution requires the company to address the specific concerns of two different examiners in two separate organizational units.
HUI, SAN MING R is identified as the busiest examiner, with a busiest_examiner_pending count of 1. Since there are 2 pending office actions in total, each examiner is responsible for one action. This distribution across 2 distinct art units and examiners requires the company to manage different prosecution tracks simultaneously within the Biotechnology & Pharmaceuticals area. Practitioners should be prepared for diverse feedback, as the company's current patenting efforts are not centralized under a single reviewer or art unit.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (50%) |
| §112 only | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| HUI, SAN MING R | 1 | 59.5% | +20.1% |
| SHTERENGARTS, SAMANTHA L | 1 | 79.5% | +8.0% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18507906 | OPHTHALMIC COMPOSITIONS OF RIFAMYCINS AND USES THEREOF | HUI, SAN MING R | 75d |
| Art Unit | Apps |
|---|---|
| 1627 | 1 |
| 1623 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18507906 | OPHTHALMIC COMPOSITIONS OF RIFAMYCINS AND USES THEREOF | HUI, SAN MING R | 1627 | §103 | Non-Final OA | 75d | Pending | Nov 13, 2023 |
| 17674648 | TREATMENT OF SKIN DISORDERS BY TOPICAL ADMINISTRATION OF VEGF INHIBITORS | SHTERENGARTS, SAMANTHA L | 1623 | §112 | Non-Final OA | — | Pending | Feb 17, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial